An overview and some recent advances in statistical methods for population-based cancer survival analysis

Size: px
Start display at page:

Download "An overview and some recent advances in statistical methods for population-based cancer survival analysis"

Transcription

1 An overview and some recent advances in statistical methods for population-based cancer survival analysis Paul W Dickman 1 Paul C Lambert 1,2 1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden 2 Department of Health Sciences, University of Leicester, UK 9 April 214

2 About me Born in Sydney Australia; studied mathematics and statistics in Newcastle (Australia). Worked in health services research; dabbled in industrial process control and quality improvement. Arrived in Sweden November 1993 for a 1 month visit to cancer epidemiology unit at Radiumhemmet. Stayed in Sweden for most of my PhD. Short Postdoc periods at Finnish Cancer Registry and Karolinska Institutet (clinical epidemiology). Joined Hans-Olov Adami s new department (now MEB) in March 1999, attracted by the strong research environment and possibilities for register-based epidemiology. Paul Dickman Population-Based Cancer Survival 9 April Research interests Primary research interests are in the development and application of methods for population-based cancer survival analysis, particularly the estimation and modeling of relative survival. Recent interest has been in presenting information on patient survival in a manner relevant for patients and clinicians. General interest in statistical aspects of the design, analysis, and reporting of epidemiological studies along with studies of disease aetiology, with particular focus on cancer epidemiology and perinatal/reproductive epidemiology. Collaborate closely with Paul Lambert (Biostatistician at University of Leicester) and Magnus Björkholm (Haematologist). Paul Dickman Population-Based Cancer Survival 9 April Overview of today s talk (to what I understand is a heterogeneous audience) Measures used in cancer control; why study patient survival. Intro to relative survival (excess mortality) and why it is the measure of choice for population-based cancer survival analysis. Flexible parametric models (Royston-Parmar models). The concept of statistical cure; cure models. Estimating crude and net probabilities of death. Partitioning excess mortality; treatment-related CVD mortality. Loss in expectation of life. Paul Dickman Population-Based Cancer Survival 9 April 214 4

3 r year 1, per y rate per 1 In ncidence or mortality Incidence Mortality Survival Lung cancer incidence, mortality and survival (age-standardised) England, , by sex Men Women Women Men Five-ye ear relativ ve surviva al (%) Year of death / Year of diagnosis Paul Dickman Population-Based Cancer Survival 9 April Lung cancer incidence in Sweden Paul Dickman Population-Based Cancer Survival 9 April How might we measure the prognosis of cancer patients? Total mortality (among the patients). Our interest is typically in net mortality (mortality associated with a diagnosis of cancer). Cause-specific mortality provides an estimate of net mortality (under certain assumptions). When estimating cause-specific mortality only those deaths which can be attributed to the cancer in question are considered to be events. cause-specific mortality = number of deaths due to cancer person-time at risk The survival times of patients who die of causes other than cancer are censored. Paul Dickman Population-Based Cancer Survival 9 April 214 7

4 Need to consider competing risks [1] Figure 1 The competing risks multi-state model. Paul Dickman Population-Based Cancer Survival 9 April Many synonyms for the same concept Net probability of death due to cancer = Probability of death in a hypothetical world where the cancer under study is the only possible cause of death Crude probability of death due to cancer = Probability of death in the real world where you may die of other causes before the cancer kills you Net probability also known as the marginal probability. Crude probability also known as the cause-specific cumulative incidence function (Geskus) or the cumulative incidence function. Paul Dickman Population-Based Cancer Survival 9 April Net (left) and crude (right) probabilities of death in men with localized prostate cancer aged 7+ at diagnosis (Cronin and Feuer [2]) Paul Dickman Population-Based Cancer Survival 9 April 214 1

5 lable at nal homepage: EUROPEAN UROLOGY 65 (214) Should we use crude or net survival? tate Cancer 1 Comparing patient survival between countries. 2 Studying temporal trends in patient survival. 3 Communicating prognosis to patients. ociation Between Use of b-blockers and Prostate cer Specific Survival: A Cohort Study of 3561 Prostate cer Patients with High-Risk or Metastatic Disease ne Hartvedt Grytli a, Morten Wang Fagerland b, Sophie D. Fosså c,d, tin Austlid Taskén a,d, * Paul Dickman Population-Based Cancer Survival 9 April rtment of Tumor Biology, Institute of Cancer Research, Oslo University Hospital, Oslo, Norway; b Unit of Biostatistics and Epidemiology, Oslo University al, Oslo, Norway; c Department of Oncology, Oslo University Hospital, Oslo, Norway; d Institute of Clinical Medicine, University of Oslo, Oslo, Norway le info Should we use crude or net survival? Abstract le history: pted January 6, 213 shed online ahead of on January 14, 213 ords: renergic receptor onist cker miology -risk prostate cancer stasis ay ate cancer ate cancer specific ality Background: We recently reported reduced prostate cancer (PCa) specific mortality for b-blocker users among patients receiving androgen-deprivation therapy in a health survey cohort including 655 PCa patients. Information on clinical characteristics was limited. Objective: To assess the association between b-blockers and PCa-specific mortality in a cohort of 3561 prostate cancer patients with high-risk or metastatic disease, and to address potential confounding from the use of statins or acetylsalicylic acid (ASA). Design, setting, and participants: Clinical information from all men reported to the Cancer Registry of Norway with a PCa diagnosis between 24 and 29 (n = ) was coupled with information on filled prescriptions between 24 and 211 from the Norwegian Prescription Database. Exclusion criteria were low- or intermediate-risk disease; planned radiotherapy or radical prostatectomy; initiation of b-blocker, ASA, or statin use after diagnosis where applicable; missing information on baseline Gleason score, prostate-specific antigen level, T stage or performance status; and missing follow-up. Outcome measurements and statistical analysis: Cox proportional hazards modelling and competing risk regression modelling were used to analyse the effects of b-blocker use on all-cause and PCa-specific mortality, respectively. Differences between b-blocker users and nonusers regarding baseline clinical characteristics were assessed by the Wilcoxon-Mann-Whitney U test, Pearson chi-square test, and Student t test. Results and limitations: Median follow-up was 39 mo. b-blocker use was associated with reduced PCa mortality (adjusted subhazard ratio:.79; 95% confidence interval [CI],.68.91; p value:.1). The observed reduction in PCa mortality was independent of the use of statins or ASA. We observed no association with all-cause mortality Paul Dickman Population-Based Cancer Survival 9 April (adjusted hazard ratio:.92; 95% CI, ). The main limitations of the study were the observational study design and short follow-up. Conclusions: b-blocker use was associated with reduced PCa-specific mortality in patients with high-risk or metastatic disease at the time of diagnosis. Our findings need validation from further observational studies. # 213 European Association of Urology. Published by Elsevier B.V. All rights reserved. Cause-specific survival can estimate net survival (assuming conditional independence) * Corresponding author. Oslo University Hospital, Institute of Cancer Research, Department of Tumor Biology, P.O. Box 4953 Nydalen, NO-424 Oslo, Norway. Tel ; Fax: Using cause-specific methods requires that reliably coded address: k.a.tasken@medisin.uio.no (K.A. Taskén). information on cause of death is available. Even when cause of death information is available to the cancer registry via death certificates, it is often vague and difficult to determine whether or not cancer is the primary cause of death. 2838/$ see back matter # 213 European Association of Urology. Published by Elsevier B.V. All rights reserved. /dx.doi.org/1.116/j.eururo How do we classify, for example, deaths due to treatment complications? Consider a patient treated with radiation therapy and chemotherapy who dies of cardiovascular disease. Do we classify this death as due entirely to cancer or due entirely to other causes? Paul Dickman Population-Based Cancer Survival 9 April

6 All-cause mortality for males with colon cancer and Finnish population Mortality Rate (per 1, person years) General population Colon cancer patients Age Paul Dickman Population-Based Cancer Survival 9 April Relative survival aims to estimate net survival (still need conditional independence) We estimate excess mortality: the difference between observed (all-cause) and expected mortality. excess = observed expected mortality mortality mortality Relative survival is the survival analog of excess mortality the relative survival ratio is defined as the observed survival in the patient group divided by the expected survival of a comparable group from the general population. relative survival ratio = observed survival proportion expected survival proportion Paul Dickman Population-Based Cancer Survival 9 April Cervical cancer in New Zealand Life table estimates of patient survival Women diagnosed with follow-up to the end of 22 Interval- Interval- Effective specific specific Cumulative Cumulative Cumulative number observed relative observed expected relative I N D W at risk survival survival survival survival survival Paul Dickman Population-Based Cancer Survival 9 April

7 Relative survival example (skin melanoma) Table 1: Number of cases (N) and 5-year observed (p), expected (p ), and relative (r) survival for males diagnosed with localised skin melanoma in Finland during Age N p p r Relative survival controls for the fact that expected mortality depends on demographic characteristics (age, sex, etc.). In addition, relative survival may, and usually does, depend on such factors. Paul Dickman Population-Based Cancer Survival 9 April Breakthrough paper in 212; Biometrics 68, An unbiased estimator for net survival [3] March 212 DOI: /j x On Estimation in Relative Survival Maja Pohar Perme, 1, Janez Stare, 1 and Jacques Estève 2 1 Department of Biostatistics and Medical Informatics, University of Ljubljana, Vrazov trg 2, SI-1 Ljubljana, Slovenia 2 Université Claude Bernard, Hospices Civils de Lyon, Service de Biostatistique, 162, Avenue Lacassagne Lyon Cedex 3, France maja.pohar@mf.uni-lj.si Summary. Estimation of relative survival has become the first and the most basic step when reporting cancer survival statistics. Standard estimators are in routine use by all cancer registries. However, it has been recently noted that these estimators do not provide information on cancer mortality that is independent of the national general population mortality. Thus they are not suitable for comparison between countries. Furthermore, the commonly used interpretation of the relative survival curve is vague and misleading. The present article attempts to remedy these basic problems. The population quantities of the traditional estimators are carefully described and their interpretation discussed. We then propose a new estimator of net survival probability that enables the desired comparability between countries. The new estimator requires no modeling and is accompanied with a straightforward variance estimate. The methods are described on real as well as simulated data. Key words: Age standardization; Cancer registry data; Competing risks; Net survival; Relative survival; Survival analysis. 1. Introduction observed hazard is larger than the population hazard. Survival probability Paul Dickman of cancer patients Population-Based has been used Cancer for many Survival Under 9 April this 214 assumption, we use the term excess hazard for the hazard due to the disease and we have the 18 years as one of the main tools for evaluation of therapeutic advances. With improved treatments and prognosis, studies relation often now have long follow-up times and it is common to have observed hazard = population hazard+ excess hazard. a substantial proportion of deaths from causes other than the cancer under study. In the usual situation, the cause of death (1) is unavailable or unreliable. Hence the field of relative survival has developed in which observed deaths are compared with A survival function derived from the excess hazard alone is termed the net survival. those expected from general population life tables. We distinguish two goals: In this article, we shall focus on three estimators in widespread use in relative survival. We will refer to them (1) To compare the observed survival (SO) tothesurvival as Ederer I (Ederer, Axtell, and Cutler, 1961), Hakulinen of Aa disease-free common groupquestion having the same indemographic our teaching. (Hakulinen, 1982), and Ederer II (Ederer et al., 1961, p. 11) characteristics as the study group. If the expected general population survival SP, the comparison is made and define them in Section 3 below. using Unless the ratiothere is reason to prefer aalthough cause-specific all three were proposed approach, as variants for we estimat- the denominator of the relative survival ratio, they have recommend oneso of (t) the following: also been interpreted as estimators of net survival. We will SR (t) = SP (t). show that this is not generally correct. When the excess Ederer II (1959 [?]) and the population hazard are not affected by any common This has been named the relative survival ratio. covariates, all methods to be discussed in this article estimate the same population quantity. In practice, however, ex- (2) To estimate Pohar survival in Perme the hypothetical (212 situation [3]) where the disease under study would be the only possible cess hazard almost always depends on demographic variables cause of death. Model-based (e.g., age) and one of the aims of this article is to find the This estimation is made possible by decomposing the population quantities that the estimators are estimating in observed hazard into the hazard due to the disease and such situations (Sections 2 and 3). The choice of method depends on the research question and that due to other causes. This decomposition can be Although the concept of net survival may seem too hypothetical to be of interest by itself, it becomes crucial carried out if the time to death due to the disease and practical considerations. the time to death due to other causes are conditionally when trying to compare cancer burden between countries, because it is independent of the general population mortality. independent given a known set of covariates. We then assume We that were the hazard recently due to other critical causes is [4] givenof Up a to paper now, most [5] authors that whoadvocated have produced large the sets of by the population mortality and, therefore, that the survival statistics (Sant et al., 29, and references therein) Pohar Perme approach; our critisism was of that particular paper C 211, The International Biometric Society 113 Which approach for estimating net survival? and not the Pohar Perme approach per se, of which we are great admirers. Paul Dickman Population-Based Cancer Survival 9 April

8 We are not suggesting Ederer II is superior We are not suggesting that the Ederer II approach is superior to the Pohar Perme approach. However, we argue that it is not as inferior as some others (e.g., Roche et al [5]) would have us believe. We do not agree with Roche et al [5] that In estimating net survival, cancer registries should abandon all classical methods and adopt the new Pohar-Perme estimator because great errors may occur.... Internally standardised, or age-specific, Ederer II estimates of 5-year and 1-year net survival are biased, although the bias is generally so small that it makes no practical difference. In short, don t panic if you have used, or are using, Ederer II. Paul Dickman Population-Based Cancer Survival 9 April European Journal of Cancer 4 (24) Review Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realisation and applications H. Brenner a, *, O. Gefeller b, T. Hakulinen c,d a Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Str. 2, D Heidelberg, Germany b Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nuremberg, Waldstrasse 6, D-9154 Erlangen, Germany c Finnish Cancer Registry, Liisankatu 21 B, FIN-17 Helsinki, Finland d Department of Public Health, University of Helsinki, FIN-17 Helsinki, Finland Received 6 August 23; received in revised form 3 September 23; accepted 21 October 23 Abstract Long-term survival rates are the most commonly used outcome measures for patients with cancer. However, traditional longterm survival statistics, which are derived by cohort-based types of analysis, essentially reflect the survival expectations of patients diagnosed many years ago. They are therefore often severely outdated at the time they become available. A couple of years ago, a new method of survival analysis, denoted period analysis, has been introduced to derive more up-to-date estimates of long-term survival rates. Paul WeDickman give a comprehensive Population-Based review of the Cancer new methodology, Survival its 9 statistical April 214background, empirical evaluation, computational realisation and applications. We conclude that period analysis is a powerful tool to provide more up-to-date cancer sur- 21 vival rates. More widespread use by cancer registries should help to increase the use of cancer survival statistics for patients, clinicians, and public health authorities. # 23 Elsevier Ltd. All rights reserved. Modelling Keywords: Neoplasms; Prognosis; excess Registries; Survival mortality 1. Introduction Relative Survival Model Long-term survival rates are the most commonly used outcome measures for patients with cancer. They are widely used to monitor progress in cancer care over time, or to compare quality of cancer care between different populations (e.g. [1 4]). Furthermore, cancer survival statistics are increasingly accessible through the Internet to clinicians and cancer patients, and their knowledge has Observed a strong impact on both clinicians management of the disease as well as patients coping strategies. However, traditional long-term survival rates, which have been derived by cohort-based types of analysis [5 7], have essentially reflected the survival expectations of patients diagnosed many years ago. They have often been severely outdated at the time they became available as they failed to account for ongoing improvements in survival over time. A few years ago, a new method of * Corresponding author. Tel.: ; fax address: brenner@dzfa.uni-heidelberg.de (H. Brenner) /$ - see front matter # 23 Elsevier Ltd. All rights reserved. doi:1.116/j.ejca h(t) = h (t) + λ(t) survival analysis, denoted period analysis, has been introduced to derive more up-to-date estimates of longterm survival rates [8,9]. Meanwhile, this methodology has undergone extensive empirical evaluation [1 14], which showed that the method provides much more upto-date estimates of long-term survival rates than traditional methods of survival analysis indeed. Furthermore, software has been developed which allows easy implementation of this new analytical tool for both absolute and relative survival rates [15]. The method is now applied to derive more up-to-date long-term survival rates in an increasing Mortality number of Rate countries [16 24]. These analyses suggest that long-term survival rates achieved by the end of the 2th century are much higher than previously suggested by traditional cohort-based analysis. For example, a recent period analysis of cancer patient survival in the United States [22] indicated that 2-year relative survival rates for all cancers combined are now approximately 51% rather than 4% as suggested by traditional cohort-based analysis (see Fig. 1). Even larger differences are seen for many common forms of cancer, such as breast cancer (65% versus 52%) or ovarian cancer (5% versus 35%). Mortality Rate = Expected Mortality Rate + Excess Cox model cannot be applied to model a difference in two rates. It is the observed mortality that drives the variance. Can use Poisson regression (Dickman et al. 24) [6]. Even better: flexible parametric models (Royston and Parmar 22 [7], Nelson et al. [8]). Paul Dickman Population-Based Cancer Survival 9 April

9 Flexible Parametric Survival Models [7, 1, 11] First introduced by Royston and Parmar (22) [7]. Parametric estimate of the baseline hazard without the usual restrictions on the shape (i.e, flexible). Applicable for standard and relative survival models. Can fit relative survival cure models (Andersson 211) [9]. Once we have a parametric expression for the baseline hazard we derive other quantities of interest (e.g., survival, hazard ratio, hazard differences, expectation of life). Paul Dickman Population-Based Cancer Survival 9 April This paper has been cited over 27, times [12] Paul Dickman Population-Based Cancer Survival 9 April The Cox model[12] h i (t x i, β) = h (t) exp (x i β) Advantage: The baseline hazard, h (t) is not directly estimated from a Cox model. Disadvantage: The baseline hazard, h (t) is not directly estimated from a Cox model. Paul Dickman Population-Based Cancer Survival 9 April

10 Quote from Sir David Cox (Reid 1994 [13]) Reid What do you think of the cottage industry that s grown up around [the Cox model]? Cox In the light of further results one knows since, I think I would normally want to tackle the problem parametrically.... I m not keen on non-parametric formulations normally. Reid So if you had a set of censored survival data today, you might rather fit a parametric model, even though there was a feeling among the medical statisticians that that wasn t quite right. Cox That s right, but since then various people have shown that the answers are very insensitive to the parametric formulation of the underlying distribution. And if you want to do things like predict the outcome for a particular patient, it s much more convenient to do that parametrically. Paul Dickman Population-Based Cancer Survival 9 April Example: survival of patients diagnosed with colon carcinoma in Finland Patients diagnosed with colon carcinoma in Finland Potential follow-up to end of 1995; censored after 1 years. Outcome is death due to colon carcinoma. Interest is in the effect of clinical stage at diagnosis (distant metastases vs no distant metastases). How might we specify a statistical model for these data? Paul Dickman Population-Based Cancer Survival 9 April Smoothed empirical hazards (cancer-specific mortality rates) sts graph, by(distant) hazard kernel(epan2) Empirical hazard Not distant Distant Paul Dickman Population-Based Cancer Survival 9 April

11 Smoothed empirical hazards on log scale sts graph, by(distant) hazard kernel(epan2) yscale(log) Empirical hazard Not distant Distant Paul Dickman Population-Based Cancer Survival 9 April Fit a Cox model to estimate the mortality rate ratio. stcox distant No. of subjects = 1328 Number of obs = 1328 No. of failures = 7122 Time at risk = LR chi2(1) = Log likelihood = Prob > chi2 = _t Haz. Ratio Std. Err. z P> z [95% C.I.] distant Paul Dickman Population-Based Cancer Survival 9 April Fitted hazards from Cox model with Efron method for ties stcox distant, efron Hazard Hazard ratio: 6.64 Not distant Distant Paul Dickman Population-Based Cancer Survival 9 April

12 Hazard Fitted hazards from parametric survival model (exponential) Not distant Distant Hazard ratio: 1.4 Hazard Ratios Cox: 6.64 Exponential: Paul Dickman Population-Based Cancer Survival 9 April Fitted hazards from parametric survival model (Weibull) Hazard Hazard ratio: 7.41 Hazard Ratios Cox: 6.64 Exponential: 1.4 Weibull: 7.41 Not distant Distant Paul Dickman Population-Based Cancer Survival 9 April Fitted hazards from parametric survival model (Weibull) Not distant Distant Hazard Paul Dickman Population-Based Cancer Survival 9 April

13 Fitted cumulative hazards from Weibull model Not distant Distant Cumulative Hazard Paul Dickman Population-Based Cancer Survival 9 April Demography and epidemiology: Practical use of the Lexis diagram in the computer age. or: Who needs the Cox-model anyway? Annual meeting of Finnish Statistical Society May 25 Revised December 25. Bendix Carstensen Steno Diabetes Center, Gentofte, Denmark & Department of Biostatistics, University of Copenhagen bxc@steno.dk Paul Dickman Population-Based Cancer Survival 9 April Hazard Fitted hazards from Poisson model (yearly intervals) Hazard Ratios Cox: 6.64 Exponential: 1.4 Weibull: 7.41 Poisson (annual): 6.89 Not distant Distant The contents of this paper was presented at the meeting of the Finnish Statistical Society in May 25 in Oulu. TheHazard slides presented ratio: 6.89 can be found on my homepage as Paul Dickman Population-Based Cancer Survival 9 April

14 Hazard Fitted hazards from Poisson model (3-months) Hazard ratio: 6.65 Hazard Ratios Cox: 6.64 Exponential: 1.4 Weibull: 7.41 Poisson (annual): 6.89 Poisson (quarter): 6.65 Not distant Distant Paul Dickman Population-Based Cancer Survival 9 April Hazard Fitted hazards from Poisson model (months) Hazard ratio: 6.64 Hazard Ratios Cox: 6.64 Exponential: 1.4 Weibull: 7.41 Poisson (annual): 6.89 Poisson (quarter): 6.65 Poisson (months): 6.64 Not distant Distant Paul Dickman Population-Based Cancer Survival 9 April Hazard Hazard ratio: 6.64 Poisson (rcs 5df for ln(time)) Hazard Ratios Cox: 6.64 Exponential: 1.4 Weibull: 7.41 Poisson (annual): 6.89 Poisson (quarter): 6.65 Poisson (months): 6.64 Not distant Distant Poisson (spline): Paul Dickman Population-Based Cancer Survival 9 April 214 4

15 Hazard Fitted hazards from flexible parametric model (5df) Hazard ratio: 6.63 Hazard Ratios Cox: 6.64 Exponential: 1.4 Weibull: 7.41 Poisson (annual): 6.89 Poisson (quarter): 6.65 Poisson (months): 6.64 Not distant Distant Poisson (spline): 6.65 Flexible parametric: Paul Dickman Population-Based Cancer Survival 9 April Flexible Parametric Models: Basic Idea Consider a Weibull survival curve. S(t) = exp ( λt γ ) If we transform to the log cumulative hazard scale. ln [H(t)] = ln[ ln(s(t))] ln [H(t)] = ln(λ) + γ ln(t) This is a linear function of ln(t) Introducing covariates gives ln [H(t x i )] = ln(λ) + γ ln(t) + x i β Rather than assuming linearity with ln(t) flexible parametric models use restricted cubic splines for ln(t). Paul Dickman Population-Based Cancer Survival 9 April Fitted cumulative hazards from Weibull model Not distant Distant Cumulative Hazard Paul Dickman Population-Based Cancer Survival 9 April

16 Flexible Parametric Models: Incorporating Splines We thus model on the log cumulative hazard scale. ln[h(t x i )] = ln [H (t)] + x i β This is a proportional hazards model. Restricted cubic splines with knots, k, are used to model the log baseline cumulative hazard. ln[h(t x i )] = η i = s (ln(t) γ, k ) + x i β For example, with 4 knots we can write ln [H(t x i )] = η i = γ + γ 1 z 1i + γ 2 z 2i + γ 3 z }{{ 3i } log baseline cumulative hazard + x i β }{{} log hazard ratios Paul Dickman Population-Based Cancer Survival 9 April We are fitting a linear predictor on the log cumulative hazard scale. Survival and Hazard Functions We can transform to the survival scale S(t x i ) = exp( exp(η i )) The hazard function is a bit more complex. h(t x i ) = ds (ln(t) γ, k ) dt exp(η i ) This involves the derivatives of the restricted cubic splines functions, although these are relatively easy to calculate. Paul Dickman Population-Based Cancer Survival 9 April Paul Dickman Population-Based Cancer Survival 9 April

17 Sensitivity to choice of knots; Simulation study by Rutherford et al. [14] Through the use of simulation, we show that provided a sufficient number of knots are used, the approximated hazard functions given by restricted cubic splines fit closely to the true function for a range of complex hazard shapes. The simulation results also highlight the insensitivity of the estimated relative effects (hazard ratios) to the correct specification of the baseline hazard. Paul Dickman Population-Based Cancer Survival 9 April

18 Simulation Study (Rutherford et al.) [14] Generate data assuming a mixture Weibull distribution. 2.5 Scenario Scenario Hazard rate Hazard rate Time Since Diagnosis (Years) Time Since Diagnosis (Years) 2.5 Scenario Scenario Hazard rate Hazard rate Time Since Diagnosis (Years) Time Since Diagnosis (Years) Fit models using restricted cubic splines. Paul Dickman Population-Based Cancer Survival 9 April Scenario 3 comparison of Log Hazard Ratios -.4 Cox Model Flexible Parametric Model Paul Dickman Population-Based Cancer Survival 9 April Choice of knots: Scenario 3 8 knots (7 df) 1. Survival Function 1.6 Hazard Function S(t) h(t) Time since diagnosis (years) Paul Dickman Population-Based Cancer Survival 9 April

19 Model Selection Estimated hazard and survival functions fairly insensitive to knot location. AIC and BIC can be used as rough guides to choose models. Not crucial (within reason) to inference based on the model. We often present a sensitivity analysis to show this. Could treat number of knots and their locations as unknowns. However, it is an area where more work is still required. Paul Dickman Population-Based Cancer Survival 9 April Implementation in Stata [1] stpm2 available from SSC. ssc install stpm2 All cause survival. stpm2 eng, scale(hazard) df(5) Relative survival. stpm2 eng, scale(hazard) df(5) hazard(rate) Time-dependent effects. stpm2 eng, scale(hazard) df(5) hazard(rate) tvc(eng) dftvc(3) Cure model. stpm2 eng, scale(hazard) df(5) hazard(rate) tvc(eng) dftvc(3) cure Paul Dickman Population-Based Cancer Survival 9 April Example using attained age as the time-scale Study from Sweden [6] comparing incidence of hip fracture of, 17,731 men diagnosed with prostate cancer treated with bilateral orchiectomy. 43,23 men diagnosed with prostate cancer not treated with bilateral orchiectomy. 362,354 men randomly selected from the general population. Study entry is 6 months post diagnosis. Outcome is femoral neck (hip) fracture. Risk of fracture varies by age. Attained age is used as the primary time-scale. Actually, two timescales, but will initially ignore time from diagnosis. Paul Dickman Population-Based Cancer Survival 9 April

20 Estimates from a proportional hazards model stset using age as the time-scale. stset dateexit,fail(frac = 1) enter(datecancer) origin(datebirth) /// id(id) scale(365.25) exit(time datebirth + 1*365.25) Cox Model. stcox noorc orc Incidence rate ratio (no orchiectomy) = 1.37 (1.28 to 1.46) Incidence rate ratio (orchiectomy) = 2.9 (1.93 to 2.27) Flexible Parametric Model. stpm2 noorc orc, df(5) scale(hazard) Incidence rate ratio (no orchiectomy) = 1.37 (1.28 to 1.46) Incidence rate ratio (orchiectomy) = 2.9 (1.93 to 2.27) Paul Dickman Population-Based Cancer Survival 9 April Proportional Hazards Incidence Rate (per 1 py's) Control No Orchiectomy Orchiectomy Age Paul Dickman Population-Based Cancer Survival 9 April Non Proportional Hazards Incidence Rate (per 1 py's) Control No Orchiectomy Orchiectomy Age Paul Dickman Population-Based Cancer Survival 9 April

21 Incidence Rate Ratio Orchiectomy vs Control Incidence Rate Ratio Age Paul Dickman Population-Based Cancer Survival 9 April Incidence Rate Difference Difference in Incidence Rates (per 1 person years) Orchiectomy vs Control Age Paul Dickman Population-Based Cancer Survival 9 April stpm2 postestimation commands Fit model (non-proportional hazards) stpm2 noorc orc, df(5) scale(h) tvc(noorc orc) dftvc(3) Fitted hazards predict h1, h zeros predict h2, h at(noorc 1 orc ) predict h3, h at(noorc orc 1) Hazard ratios predict hr2, hrnum(noorc 1) ci predict hr3, hrnum(orc 1) ci Hazard differences predict hdiff2, hdiff1(noorc 1) ci predict hdiff3, hdiff1(orc 1) ci Paul Dickman Population-Based Cancer Survival 9 April

22 Net Survival (revisited) Relative Survival aims to estimate net survival. This is the probability of not dying of cancer in the hypothetical world where it is impossible to die of other causes. Key Assumptions Independence between mortality due to cancer and mortality due to other causes & an appropriate estimate of expected survival. Same interpretation/assumption for cause-specific survival. We also assume that we have modelled covariates appropriately. Paul Dickman Population-Based Cancer Survival 9 April Crude and Net Probabilities Net Probability of Death Due to Cancer = Probability of death due to cancer in a hypothetical world, where the cancer under study is the only possible cause of death Crude Probability of Death Due to Cancer = Probability of death due to cancer in the real world, where you may die of other causes before the cancer kills you Net probability also known as the marginal probability. Crude probability also known as the cause-specific cumulative incidence function (Geskus) or the cumulative incidence function. Paul Dickman Population-Based Cancer Survival 9 April Brief Mathematical Details [15] h(t) = h (t) + λ(t) - all-cause mortality rate h (t) - expected mortality rate λ(t) - excess mortality rate S (t) - Expected Survival R(t) - Relative Survival ( t ) Net Prob of Death = 1 R(t) = 1 exp λ(t) Crude Prob of Death (cancer) = Crude Prob of Death (other causes) = t t S (t)r(t)λ(t) S (t)r(t)h (t) Paul Dickman Population-Based Cancer Survival 9 April

23 Probabilities of death due to prostate cancer [16] Net probability of death (1 relative survival) Dead (PC) Alive Age 75 at diagnosis Crude probability of death Dead (PC) Dead (other causes) alive Age 75 at diagnosis Net probability of death (1 relative survival) Dead (PC) Alive Age 6 at diagnosis Crude probability of death Dead (PC) Dead (other causes) Alive Age 6 at diagnosis The inserted numbers represent the 1 year probabilities of death Paul Dickman Population-Based Cancer Survival 9 April What is cure? Medical cure occurs when all signs of cancer have been removed in a patient; this is an individual-level definition of cure. It is difficult to prove that a patient is medically cured. Population or statistical cure occurs when mortality among patients with the disease returns to the same level as that expected for the general population. Equivalently the excess mortality rate approaches zero. This is a population-level definition of cure. When the excess mortality reaches (and stays) at zero, the relative survival curve is seen to reach a plateau. Paul Dickman Population-Based Cancer Survival 9 April Plateau for relative survival 1..8 Relative Survival Years from Diagnosis Paul Dickman Population-Based Cancer Survival 9 April

24 Mixture cure model Mixture cure model S(t) = S (t)(π + (1 π)s u (t)); λ(t) = h (t) + (1 π)fu(t) π+(1 π)s u(t) S (t) is the expected survival. π is the proportion cured (the cure fraction). (1 π) is the proportion uncured (those bound to die ). S u (t) is the net survival for the uncured group. The excess mortality rate has an asymptote at zero. See De Angelis et al. [17], Verdecchia et al. [18] and Lambert et al.[19] for details. Paul Dickman Population-Based Cancer Survival 9 April Cure models: Interpreting changes over time Survival of Uncured (c) Cure Fraction Adapted from Verdeccia (1998) (a) (d) (b) (a) General Improvement (b) Selective Improvment (c) Improved palliative care or lead time (d) Inclusion of subjects with no excess risk Paul Dickman Population-Based Cancer Survival 9 April Time trends for cancer of the colon age <5 [2] Cure Fraction and Median Survival of Uncured Age Group: <5 1. Cure Fraction Median Survival Cure Fraction Median Survival Year of Diagnosis. Paul Dickman Population-Based Cancer Survival 9 April 214 7

25 Andersson 21 [21]: trends for AML Aged 19 4 at diagnosis Aged 41 6 at diagnosis Cure proportion Median survival time Cure proportion Median survival time Year of diagnosis Year of diagnosis Aged 61 7 at diagnosis Aged 71 8 at diagnosis Cure proportion Median survival time Cure proportion Median survival time Year of diagnosis Year of diagnosis Cure proportion Median survival time 95% CI Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models One limitation of parametric cure models is that a functional form has to be specified Hard to fit survival functions flexible enough to capture high excess hazard within a few months from diagnosis Hard to fit high cure proportion Flexible parametric approach for cure models enable inclusion of these patient groups Andersson et al. BMC Medical Research Methodology 211, 11:96 RESEARCH ARTICLE Open Access Estimating and modelling cure in populationbased cancer studies within the framework of flexible parametric survival models Therese ML Andersson 1*, Paul W Dickman 1, Sandra Eloranta 1 and Paul C Lambert 1,2 Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models When cure is reached the excess hazard rate is zero, and the cumulative excess hazard is constant By incorporating an extra constraint on the log cumulative excess hazard after the last knot, so that we force it not only to be linear but also to have zero slope, we are able to estimate the cure proportion This is done by calculating the splines backwards and introduce a constraint on the linear spline parameter in the regression model Paul Dickman Population-Based Cancer Survival 9 April

26 Flexible parametric cure models Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models The relative survival function from the flexible parametric survival model, with splines calculated backwards and with restriction on the parameter for the linear spline variable is defined as R(t) = exp( exp(γ + γ 2 z γ K 1 z K 1 )) which can be written as where π = exp( exp(γ )). R(t) = π exp(γ 2z γ K 1 z K 1 ), Paul Dickman Population-Based Cancer Survival 9 April Comparison with a non-mixture model The flexible parametric cure model is a special case of a non-mixture cure model with and π = exp( exp(γ )) F Z (t) = exp(γ 2 z γ K 1 z K 1 ). This is a proportional hazards model as long as no time-dependent effects are modelled. Paul Dickman Population-Based Cancer Survival 9 April

27 Flexible parametric cure models Incorporating covariates gives, and π = exp( exp(γ + xβ)) F Z (t) = exp(γ 2 z γ K 1 z K 1 + D s (ln(t); γ i ) x i ) the constant parameters are used to model the cure proportion i=1 the time-dependent parameters are used to model the distribution function constraint of a zero effect for the linear spline term has to be incorporated for each spline function Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models Flexible parametric cure models can be fitted in Stata by adding a cure option to the stpm2 command stpm2 cage2-cage4, scale(h) df(5) bhazard(rate) /// tvc(cage2-cage4) dftvc(3) cure The spline variables will be calculated backwards, the constraint will be added for the linear spline parameters and the default knot distribution will be slightly different Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models Log likelihood = Number of obs = xb Coef. Std. Err. z P> z [95% Conf. Interval] cage cage cage _rcs _rcs _rcs _rcs _rcs5 (omitted) _rcs_cage _rcs_cage _rcs_cage23 (omitted) _rcs_cage _rcs_cage _rcs_cage33 (omitted) _rcs_cage _rcs_cage _rcs_cage43 (omitted) _cons Paul Dickman Population-Based Cancer Survival 9 April

28 Flexible parametric cure models The cure proportion, the survival function for the uncured and the median survival time for uncured can be estimated using the predict command. predict cure, cure. predict medst, centile(5) uncured. predict survunc, survival uncured. predict surv, survival Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models Paul Dickman Population-Based Cancer Survival 9 April

29 Flexible parametric cure models Paul Dickman Population-Based Cancer Survival 9 April Flexible parametric cure models Paul Dickman Population-Based Cancer Survival 9 April Partitioning Excess Mortality (Eloranta [22, 23]) We have extended flexible parametric models for relative survival to simultaneously estimate the excess mortality due to diseases of the circulatory system (DCS) and the remaining excess mortality among patients diagnosed with Hodgkin lymphoma. Results are presented both as excess mortality rates and crude probabilities of death. The outcomes (DCS and non-dcs mortality) can be regarded as competing events and the total excess mortality is partitioned using ideas from classical competing risks theory. The model requires population mortality files stratified on cause of death (i.e., DCS and other deaths) to identify those deaths in excess of expected. Paul Dickman Population-Based Cancer Survival 9 April

30 Excess mortality for males with Hodgkin lymphoma 25 Age at Diagnosis: Age at Diagnosis: Excess Mortality (per 1, p yrs) Excess Mortality (per 1, p yrs) Years Since Diagnosis Years Since Diagnosis Excess DCS Mortality Remaining Excess Mortality 95% C.I Paul Dickman Population-Based Cancer Survival 9 April Temporal trends in 2-year probability of death 2 year Probability of Death Age at Diagnosis: Year of Diagnosis Predicted future 2 year Probability of Death Age at Diagnosis: Year of Diagnosis 2 year Probability of Death Age at Diagnosis: Year of Diagnosis Predicted future 2 year Probability of Death Age at Diagnosis: Year of Diagnosis Dead (Excess DCS Mortality) Dead (Other Causes) Dead (Remaining Excess HL Mortality) 95 % CI Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life A useful summary measure of survival is the mean survival, life expectancy The loss in expectation of life is the difference between the mean expected survival (if not diagnosed with cancer) and the mean observed survival (for cancer patients) Quantify disease burden in the society how many life-years are lost due to the disease? Quantify differences between socio-economic groups or countries, how many life-years are lost in the population due to differences in cancer patient survival between groups? how many life-years would be gained if England had the same cancer patient survival as Sweden? Quantify the impact a cancer diagnosis has on a patient s life expectancy Paul Dickman Population-Based Cancer Survival 9 April

31 Loss in expectation of life Survival Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life Survival Mean observed survival 5.3 years Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life Survival Mean expected survival 1.5 years Paul Dickman Population-Based Cancer Survival 9 April

32 Loss in expectation of life Survival Difference 5.2 years Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life Survival Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life Even though we are now interested in the all-cause survival we will use a relative survival approach S(t) = S (t) R(t) h(t) = h (t) + λ(t) Easier to extrapolate R(t) than S(t) Has been done for grouped data (life tables) [24], by assuming λ(t) = or λ(t) = c after some point in time Paul Dickman Population-Based Cancer Survival 9 April

33 Loss in expectation of life Approaches for extrapolating relative survival 1 Assume cure, i.e no excess hazard after a certain point in time, λ(t) = 2 Assume constant excess hazard after a certain point in time, λ(t) = c (exponential) 3 Assume the excess hazard given by the spline parameters from the model without imposing extra constraints, (Weibull) The all-cause survival can then be estimated by multiplying with the (extrapolated) expected survival Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life, colon cancer Survival Colon cancer, Age 6 69, Males Mean survival: 5.3 years 6.6 years 5.1 years 5.4 years Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life, breast cancer Breast cancer Survival Age 5 59 Age 6 69 Survival Age 7 79 Age K M estimates of all cause survival Extrapolating relative survival 95% CI for K M Relative survival, constant EH Paul Dickman Population-Based Cancer Survival 9 April

34 Loss in expectation of life, melanoma Melanoma Survival Age 5 59 Age 6 69 Survival Age 7 79 Age K M estimates of all cause survival Extrapolating relative survival 95% CI for K M Relative survival, cure Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life, bladder cancer Bladder cancer Survival Age 5 59 Age 6 69 Survival Age 7 79 Age K M estimates of all cause survival Extrapolating relative survival 95% CI for K M Relative survival, constant EH Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life, colon cancer Relative survival 1 Males 1 Females year RSR year RSR Year of diagnosis Year of diagnosis Age 55 Age 65 Age 75 Age 85 Paul Dickman Population-Based Cancer Survival 9 April 214 1

35 Loss in expectation of life, colon cancer Males, Age 55 Males, Age Years 15 1 Years Year of diagnosis Year of diagnosis Males, Age 75 Males, Age Years 15 1 Years Year of diagnosis Year of diagnosis Life expectancy of general population Life expectancy of cancer patients Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life, colon cancer Loss in expectation of life Males Females Years Years Year of diagnosis Year of diagnosis Age 55 Age 65 Age 75 Age 85 Paul Dickman Population-Based Cancer Survival 9 April Loss in expectation of life Males Females Years Proportion Years Proportion Age at diagnosis Age at diagnosis Years of expected life lost (left y axis) Proportion of expected life lost (right y axis) Paul Dickman Population-Based Cancer Survival 9 April

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival

Overview. All-cause mortality for males with colon cancer and Finnish population. Relative survival An overview and some recent advances in statistical methods for population-based cancer survival analysis: relative survival, cure models, and flexible parametric models Paul W Dickman 1 Paul C Lambert

More information

About me. An overview and some recent advances in statistical methods for population-based cancer survival analysis. Research interests

About me. An overview and some recent advances in statistical methods for population-based cancer survival analysis. Research interests An overview and some recent advances in statistical methods for population-based cancer survival analysis Paul W Dickman Paul C Lambert,2 Department of Medical Epidemiology and Biostatistics, Karolinska

More information

Quantifying cancer patient survival; extensions and applications of cure models and life expectancy estimation

Quantifying cancer patient survival; extensions and applications of cure models and life expectancy estimation From the Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden Quantifying cancer patient survival; extensions and applications of cure models and life expectancy

More information

An overview and some recent advances in statistical methods for population-based cancer survival analysis

An overview and some recent advances in statistical methods for population-based cancer survival analysis An overview and some recent advances in statistical methods for population-based cancer survival analysis Paul W Dickman 1 Paul C Lambert 1,2 1 Department of Medical Epidemiology and Biostatistics, Karolinska

More information

Up-to-date survival estimates from prognostic models using temporal recalibration

Up-to-date survival estimates from prognostic models using temporal recalibration Up-to-date survival estimates from prognostic models using temporal recalibration Sarah Booth 1 Mark J. Rutherford 1 Paul C. Lambert 1,2 1 Biostatistics Research Group, Department of Health Sciences, University

More information

Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies

Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies Estimating and Modelling the Proportion Cured of Disease in Population Based Cancer Studies Paul C Lambert Centre for Biostatistics and Genetic Epidemiology, University of Leicester, UK 12th UK Stata Users

More information

Estimating and modelling relative survival

Estimating and modelling relative survival Estimating and modelling relative survival Paul W. Dickman Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden paul.dickman@ki.se Regstat 2009 Workshop on Statistical

More information

Sarwar Islam Mozumder 1, Mark J Rutherford 1 & Paul C Lambert 1, Stata London Users Group Meeting

Sarwar Islam Mozumder 1, Mark J Rutherford 1 & Paul C Lambert 1, Stata London Users Group Meeting 2016 Stata London Users Group Meeting stpm2cr: A Stata module for direct likelihood inference on the cause-specific cumulative incidence function within the flexible parametric modelling framework Sarwar

More information

M. J. Rutherford 1,*, T. M-L. Andersson 2, H. Møller 3, P.C. Lambert 1,2.

M. J. Rutherford 1,*, T. M-L. Andersson 2, H. Møller 3, P.C. Lambert 1,2. Understanding the impact of socioeconomic differences in breast cancer survival in England and Wales: avoidable deaths and potential gain in expectation of life. M. J. Rutherford 1,*, T. M-L. Andersson

More information

Analysing population-based cancer survival settling the controversies

Analysing population-based cancer survival settling the controversies Pohar Perme et al. BMC Cancer (216) 16:933 DOI 1.1186/s12885-16-2967-9 RESEARCH ARTICLE Open Access Analysing population-based cancer survival settling the controversies Maja Pohar Perme 1*, Jacques Estève

More information

Assessment of lead-time bias in estimates of relative survival for breast cancer

Assessment of lead-time bias in estimates of relative survival for breast cancer Assessment of lead-time bias in estimates of relative survival for breast cancer Therese M-L Andersson a,, Mark J Rutherford b, Keith Humphreys a a Department of Medical Epidemiology and Biostatistics,

More information

An Overview of Survival Statistics in SEER*Stat

An Overview of Survival Statistics in SEER*Stat An Overview of Survival Statistics in SEER*Stat National Cancer Institute SEER Program SEER s mission is to provide information on cancer statistics in an effort to reduce the burden of cancer among the

More information

MEASURING CANCER CURE IN IRELAND

MEASURING CANCER CURE IN IRELAND MEASURING CANCER CURE IN IRELAND 2019 ABBREVIATIONS 95% CI 95% confidence interval APC Annual percentage change ASR Age-standardised rate (European standard population) IARC International Agency for Research

More information

ASSESSMENT OF LEAD-TIME BIAS IN ESTIMATES OF RELATIVE SURVIVAL FOR BREAST CANCER

ASSESSMENT OF LEAD-TIME BIAS IN ESTIMATES OF RELATIVE SURVIVAL FOR BREAST CANCER ASSESSMENT OF LEAD-TIME BIAS IN ESTIMATES OF RELATIVE SURVIVAL FOR BREAST CANCER Therese M-L Andersson 1, Mark Rutherford 2, Keith Humphreys 1 1 Karolinska Institutet, Stockholm, Sweden 2 University of

More information

Cancer Incidence Predictions (Finnish Experience)

Cancer Incidence Predictions (Finnish Experience) Cancer Incidence Predictions (Finnish Experience) Tadeusz Dyba Joint Research Center EPAAC Workshop, January 22-23 2014, Ispra Rational for making cancer incidence predictions Administrative: to plan the

More information

Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision

Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision Journal of Clinical Epidemiology 59 (2006) 570 575 ORIGINAL ARTICLES Period estimates of cancer patient survival are more up-to-date than estimates even at comparable levels of precision Hermann Brenner

More information

The improved cure fraction for esophageal cancer in Linzhou city

The improved cure fraction for esophageal cancer in Linzhou city Liu et al. BMC Cancer (2018) 18:949 https://doi.org/10.1186/s12885-018-4867-7 RESEARCH ARTICLE Open Access The improved cure fraction for esophageal cancer in Linzhou city Shuzheng Liu 1, Lanwei Guo 1,

More information

Cancer survival and prevalence in Tasmania

Cancer survival and prevalence in Tasmania Cancer survival and prevalence in Tasmania 1978-2008 Cancer survival and prevalence in Tasmania 1978-2008 Tasmanian Cancer Registry University of Tasmania Menzies Research Institute Tasmania 17 Liverpool

More information

Multi-state survival analysis in Stata

Multi-state survival analysis in Stata Multi-state survival analysis in Stata Michael J. Crowther Biostatistics Research Group Department of Health Sciences University of Leicester, UK michael.crowther@le.ac.uk Italian Stata Users Group Meeting

More information

Age-standardised Net Survival & Cohort and Period Net Survival Estimates

Age-standardised Net Survival & Cohort and Period Net Survival Estimates Cancer survival analysis using population-based data Granada, 27-28 March 2017 Age-standardised Net Survival & Cohort and Period Net Survival Estimates Cancer survival analysis using population-based data

More information

Multivariate dose-response meta-analysis: an update on glst

Multivariate dose-response meta-analysis: an update on glst Multivariate dose-response meta-analysis: an update on glst Nicola Orsini Unit of Biostatistics Unit of Nutritional Epidemiology Institute of Environmental Medicine Karolinska Institutet http://www.imm.ki.se/biostatistics/

More information

Measuring and predicting cancer incidence, prevalence and survival in Finland

Measuring and predicting cancer incidence, prevalence and survival in Finland Measuring and predicting cancer incidence, prevalence and survival in Finland Timo Hakulinen and Karri Seppä Finnish Cancer Registry- the Institute for Statistical and Epidemiological Cancer Research ABSTRACT

More information

Application of EM Algorithm to Mixture Cure Model for Grouped Relative Survival Data

Application of EM Algorithm to Mixture Cure Model for Grouped Relative Survival Data Journal of Data Science 5(2007), 41-51 Application of EM Algorithm to Mixture Cure Model for Grouped Relative Survival Data Binbing Yu 1 and Ram C. Tiwari 2 1 Information Management Services, Inc. and

More information

Liver Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance

Liver Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance December 212 21 Report on Cancer Statistics in Alberta Acknowledgements 2 This report was made possible through Alberta Health Services,, and the many contributions of staff and management across Alberta

More information

Measuring cancer survival in populations: relative survival vs cancer-specific survival

Measuring cancer survival in populations: relative survival vs cancer-specific survival Int. J. Epidemiol. Advance Access published February 8, 2010 Published by Oxford University Press on behalf of the International Epidemiological Association ß The Author 2010; all rights reserved. International

More information

Immortal Time Bias and Issues in Critical Care. Dave Glidden May 24, 2007

Immortal Time Bias and Issues in Critical Care. Dave Glidden May 24, 2007 Immortal Time Bias and Issues in Critical Care Dave Glidden May 24, 2007 Critical Care Acute Respiratory Distress Syndrome Patients on ventilator Patients may recover or die Outcome: Ventilation/Death

More information

Biostatistics II

Biostatistics II Biostatistics II 514-5509 Course Description: Modern multivariable statistical analysis based on the concept of generalized linear models. Includes linear, logistic, and Poisson regression, survival analysis,

More information

2012 Report on Cancer Statistics in Alberta

2012 Report on Cancer Statistics in Alberta 212 Report on Cancer Statistics in Alberta Kidney Cancer Surveillance & Reporting CancerControl AB February 215 Acknowledgements This report was made possible through Surveillance & Reporting, Cancer Measurement

More information

Colorectal Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance

Colorectal Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance December 212 21 Acknowledgements 2 This report was made possible through Alberta Health Services,, and the many contributions of staff and management across Alberta Health Services as well as external

More information

Modelled prevalence. Marc COLONNA. January 22-23, 2014 Ispra

Modelled prevalence. Marc COLONNA. January 22-23, 2014 Ispra STATE OF ART OF METHODS FOR THE ANALYSIS OF POPULATION-BASED CANCER DATA : Session 4 :PREVALENCE Modelled prevalence Marc COLONNA Isere Cancer Registry FRANCIM network (France) January 22-23, 2014 Ispra

More information

Leukemia Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance

Leukemia Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance December 212 21 Report on Cancer Statistics in Alberta Report on Cancer Statistics in Alberta Acknowledgements 2 This report was made possible through Alberta Health Services,, and the many contributions

More information

Kidney Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance

Kidney Cancer Report on Cancer Statistics in Alberta. December Cancer Care. Cancer Surveillance December 212 21 Report on Cancer Statistics in Alberta Report on Cancer Statistics in Alberta Acknowledgements 2 This report was made possible through Alberta Health Services,, and the many contributions

More information

Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium

Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium Original article Annals of Oncology 16: 981 986, 2005 doi:10.1093/annonc/mdi186 Published online 22 April 2005 Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium

More information

2012 Report on Cancer Statistics in Alberta

2012 Report on Cancer Statistics in Alberta 212 Report on Cancer Statistics in Alberta Leukemia Surveillance & Reporting CancerControl AB February 215 Acknowledgements This report was made possible through Surveillance & Reporting, Cancer Measurement

More information

Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel

Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Estimating and comparing cancer progression risks under varying surveillance protocols: moving beyond the Tower of Babel Jane Lange March 22, 2017 1 Acknowledgements Many thanks to the multiple project

More information

Methodology for the Survival Estimates

Methodology for the Survival Estimates Methodology for the Survival Estimates Inclusion/Exclusion Criteria Cancer cases are classified according to the International Classification of Diseases for Oncology - Third Edition (ICDO-3) Disease sites

More information

Deprivation and Cancer Survival in Scotland: Technical Report

Deprivation and Cancer Survival in Scotland: Technical Report Deprivation and Cancer Survival in Scotland: Technical Report 1 Foreword We are delighted to publish the first report from the Macmillan Cancer Support partnership with the Information Services Division.

More information

Regression Discontinuity Designs: An Approach to Causal Inference Using Observational Data

Regression Discontinuity Designs: An Approach to Causal Inference Using Observational Data Regression Discontinuity Designs: An Approach to Causal Inference Using Observational Data Aidan O Keeffe Department of Statistical Science University College London 18th September 2014 Aidan O Keeffe

More information

Issues for analyzing competing-risks data with missing or misclassification in causes. Dr. Ronny Westerman

Issues for analyzing competing-risks data with missing or misclassification in causes. Dr. Ronny Westerman Issues for analyzing competing-risks data with missing or misclassification in causes Dr. Ronny Westerman Institute of Medical Sociology and Social Medicine Medical School & University Hospital July 27,

More information

IJC International Journal of Cancer

IJC International Journal of Cancer IJC International Journal of Cancer Cure of cancer for seven cancer sites in the Flemish Region Geert Silversmit 1, David Jegou 1, Evelien Vaes 1, Elke Van Hoof 2, Els Goetghebeur 3 and Liesbet Van Eycken

More information

Calibrating Time-Dependent One-Year Relative Survival Ratio for Selected Cancers

Calibrating Time-Dependent One-Year Relative Survival Ratio for Selected Cancers ISSN 1995-0802 Lobachevskii Journal of Mathematics 2018 Vol. 39 No. 5 pp. 722 729. c Pleiades Publishing Ltd. 2018. Calibrating Time-Dependent One-Year Relative Survival Ratio for Selected Cancers Xuanqian

More information

Trends in Cancer Survival in NSW 1980 to 1996

Trends in Cancer Survival in NSW 1980 to 1996 Trends in Cancer Survival in NSW 19 to 1996 Xue Q Yu Dianne O Connell Bruce Armstrong Robert Gibberd Cancer Epidemiology Research Unit Cancer Research and Registers Division The Cancer Council NSW August

More information

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study EUROCARE-5 on-line database Data and methods Extract from Cancer survival in Europe 1999 2007 by country and age: results of EUROCARE-5 a population-based study De Angelis R, Sant M, Coleman MP, Francisci

More information

Modeling unobserved heterogeneity in Stata

Modeling unobserved heterogeneity in Stata Modeling unobserved heterogeneity in Stata Rafal Raciborski StataCorp LLC November 27, 2017 Rafal Raciborski (StataCorp) Modeling unobserved heterogeneity November 27, 2017 1 / 59 Plan of the talk Concepts

More information

Estimating relative survival: An analysis of bias introduced by outdated life tables. Larry Ellison Health Statistics Division Ottawa, June 24, 2014

Estimating relative survival: An analysis of bias introduced by outdated life tables. Larry Ellison Health Statistics Division Ottawa, June 24, 2014 Estimating relative survival: An analysis of bias introduced by outdated life tables Larry Ellison Health Statistics Division Ottawa, June 24, 2014 Background relative survival defined... The ratio of

More information

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy

When PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA

More information

Lifetime vs. 10-year risk to allocate treatments for the primary prevention of cardiovascular disease

Lifetime vs. 10-year risk to allocate treatments for the primary prevention of cardiovascular disease Lifetime vs. 10-year risk to allocate treatments for the primary prevention of cardiovascular disease Eleni Rapsomaniki Farr Institute for Health Informatics Research, Epidemiology & Public Health University

More information

Challenges in design and analysis of large register-based epidemiological studies

Challenges in design and analysis of large register-based epidemiological studies FMS/DSBS autumn meeting 2014 Challenges in design and analysis of large register-based epidemiological studies Caroline Weibull & Anna Johansson Department of Medical Epidemiology and Biostatistics (MEB)

More information

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method

Lecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method Biost 590: Statistical Consulting Statistical Classification of Scientific Studies; Approach to Consulting Lecture Outline Statistical Classification of Scientific Studies Statistical Tasks Approach to

More information

Survival in Teenagers and Young. Adults with Cancer in the UK

Survival in Teenagers and Young. Adults with Cancer in the UK Survival in Teenagers and Young Adults with Cancer in the UK Survival in Teenagers and Young Adults (TYA) with Cancer in the UK A comparative report comparing TYA cancer survival with that of children

More information

Using dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme

Using dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme Using dynamic prediction to inform the optimal intervention time for an abdominal aortic aneurysm screening programme Michael Sweeting Cardiovascular Epidemiology Unit, University of Cambridge Friday 15th

More information

Estimating relative survival using the strel command

Estimating relative survival using the strel command Estimating relative survival using the strel command Bernard Rachet 7 September 2007 Stata workshop - Stockholm 1 Basis concepts Estimation of disease-specific lethality in a group of cancer patients.

More information

MODEL SELECTION STRATEGIES. Tony Panzarella

MODEL SELECTION STRATEGIES. Tony Panzarella MODEL SELECTION STRATEGIES Tony Panzarella Lab Course March 20, 2014 2 Preamble Although focus will be on time-to-event data the same principles apply to other outcome data Lab Course March 20, 2014 3

More information

A Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers

A Methodological Issue in the Analysis of Second-Primary Cancer Incidence in Long-Term Survivors of Childhood Cancers American Journal of Epidemiology Copyright 2003 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 158, No. 11 Printed in U.S.A. DOI: 10.1093/aje/kwg278 PRACTICE OF EPIDEMIOLOGY

More information

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida

LOGO. Statistical Modeling of Breast and Lung Cancers. Cancer Research Team. Department of Mathematics and Statistics University of South Florida LOGO Statistical Modeling of Breast and Lung Cancers Cancer Research Team Department of Mathematics and Statistics University of South Florida 1 LOGO 2 Outline Nonparametric and parametric analysis of

More information

Report on Cancer Statistics in Alberta. Melanoma of the Skin

Report on Cancer Statistics in Alberta. Melanoma of the Skin Report on Cancer Statistics in Alberta Melanoma of the Skin November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of

More information

Do morphology and stage explain the inferior lung cancer survival in Denmark?

Do morphology and stage explain the inferior lung cancer survival in Denmark? Eur Respir J 1999; 13: 430±435 Printed in UK ± all rights reserved Copyright #ERS Journals Ltd 1999 European Respiratory Journal ISSN 0903-1936 Do morphology and stage explain the inferior lung cancer

More information

Nation nal Cancer Institute. Prevalence Projections: The US Experience

Nation nal Cancer Institute. Prevalence Projections: The US Experience Nation nal Cancer Institute Prevalence Projections: The US Experience State of Art Methods for the Analysis of Population- Based Cancer Data January 22-23, 2014 Ispra, Italy U.S. DEPARTMENT OF HEALTH AND

More information

Generation times in epidemic models

Generation times in epidemic models Generation times in epidemic models Gianpaolo Scalia Tomba Dept Mathematics, Univ of Rome "Tor Vergata", Italy in collaboration with Åke Svensson, Dept Mathematics, Stockholm University, Sweden Tommi Asikainen

More information

Downloaded from:

Downloaded from: Gauci, D; Allemani, C; Woods, L (2016) Population-level cure of colorectal cancer in Malta: An analysis of patients diagnosed between 1995 and 2004. Cancer epidemiology, 42. pp. 32-38. ISSN 1877-7821 DOI:

More information

Analysis of TB prevalence surveys

Analysis of TB prevalence surveys Workshop and training course on TB prevalence surveys with a focus on field operations Analysis of TB prevalence surveys Day 8 Thursday, 4 August 2011 Phnom Penh Babis Sismanidis with acknowledgements

More information

Landmarking, immortal time bias and. Dynamic prediction

Landmarking, immortal time bias and. Dynamic prediction Landmarking and immortal time bias Landmarking and dynamic prediction Discussion Landmarking, immortal time bias and dynamic prediction Department of Medical Statistics and Bioinformatics Leiden University

More information

Biological Cure. Margaret R. Stedman, Ph.D. MPH Angela B. Mariotto, Ph.D.

Biological Cure. Margaret R. Stedman, Ph.D. MPH Angela B. Mariotto, Ph.D. Using Cure Models to Estimate Biological Cure Margaret R. Stedman, Ph.D. MPH Angela B. Mariotto, Ph.D. Data Modeling Branch Surveillance Research Program Division of Cancer Control and Population Sciences

More information

Report on Cancer Statistics in Alberta. Kidney Cancer

Report on Cancer Statistics in Alberta. Kidney Cancer Report on Cancer Statistics in Alberta Kidney Cancer November 29 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the Report

More information

Estimation and prediction in multistate models

Estimation and prediction in multistate models Estimation and prediction in multistate models Bendix Carstensen Steno Diabetes Center, Gentofte, Denmark & Department of Biostatistics, University of Copenhagen b@bxc.dk http://bendixcarstensen.com University

More information

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,

More information

Spatiotemporal models for disease incidence data: a case study

Spatiotemporal models for disease incidence data: a case study Spatiotemporal models for disease incidence data: a case study Erik A. Sauleau 1,2, Monica Musio 3, Nicole Augustin 4 1 Medicine Faculty, University of Strasbourg, France 2 Haut-Rhin Cancer Registry 3

More information

Supplementary Information for Avoidable deaths and random variation in patients survival

Supplementary Information for Avoidable deaths and random variation in patients survival Supplementary Information for Avoidable deaths and random variation in patients survival by K Seppä, T Haulinen and E Läärä Supplementary Appendix Relative survival and excess hazard of death The relative

More information

Trends in Irish cancer incidence with predictions to 2020

Trends in Irish cancer incidence with predictions to 2020 Trends in Irish cancer incidence 1994-22 with predictions to 22 Trends in Irish cancer incidence 1994-22 with projections to 22 National Cancer Registry June 26 1 Acknowledgements. I would like to thank

More information

Selection and Combination of Markers for Prediction

Selection and Combination of Markers for Prediction Selection and Combination of Markers for Prediction NACC Data and Methods Meeting September, 2010 Baojiang Chen, PhD Sarah Monsell, MS Xiao-Hua Andrew Zhou, PhD Overview 1. Research motivation 2. Describe

More information

EUROPEAN UROLOGY 62 (2012)

EUROPEAN UROLOGY 62 (2012) EUROPEAN UROLOGY 62 (2012) 745 752 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Allison S. Glass, Matthew R. Cooperberg and

More information

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time.

Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Supplement for: CD4 cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, gender and calendar time. Anne Cori* 1, Michael Pickles* 1, Ard van Sighem 2, Luuk Gras 2,

More information

Basic Biostatistics. Chapter 1. Content

Basic Biostatistics. Chapter 1. Content Chapter 1 Basic Biostatistics Jamalludin Ab Rahman MD MPH Department of Community Medicine Kulliyyah of Medicine Content 2 Basic premises variables, level of measurements, probability distribution Descriptive

More information

CANCER IN NSW ABORIGINAL PEOPLES. Incidence, mortality and survival September 2012

CANCER IN NSW ABORIGINAL PEOPLES. Incidence, mortality and survival September 2012 CANCER IN NSW ABORIGINAL PEOPLES Incidence, mortality and survival September 2012 CANCER IN NSW ABORIGINAL PEOPLES Contents Tables 1 Figures 2 Message from the Chief Cancer Officer 4 Executive summary

More information

BIOSTATISTICAL METHODS AND RESEARCH DESIGNS. Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA

BIOSTATISTICAL METHODS AND RESEARCH DESIGNS. Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA BIOSTATISTICAL METHODS AND RESEARCH DESIGNS Xihong Lin Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA Keywords: Case-control study, Cohort study, Cross-Sectional Study, Generalized

More information

What is Multilevel Modelling Vs Fixed Effects. Will Cook Social Statistics

What is Multilevel Modelling Vs Fixed Effects. Will Cook Social Statistics What is Multilevel Modelling Vs Fixed Effects Will Cook Social Statistics Intro Multilevel models are commonly employed in the social sciences with data that is hierarchically structured Estimated effects

More information

The Linked SEER-Medicare Data and Cancer Effectiveness Research

The Linked SEER-Medicare Data and Cancer Effectiveness Research The Linked SEER-Medicare Data and Cancer Effectiveness Research Arnold L. Potosky, PhD Professor of Oncology Director of Health Services Research Georgetown University Medical Center Lombardi Comprehensive

More information

Reflection Questions for Math 58B

Reflection Questions for Math 58B Reflection Questions for Math 58B Johanna Hardin Spring 2017 Chapter 1, Section 1 binomial probabilities 1. What is a p-value? 2. What is the difference between a one- and two-sided hypothesis? 3. What

More information

A Bayesian Perspective on Unmeasured Confounding in Large Administrative Databases

A Bayesian Perspective on Unmeasured Confounding in Large Administrative Databases A Bayesian Perspective on Unmeasured Confounding in Large Administrative Databases Lawrence McCandless lmccandl@sfu.ca Faculty of Health Sciences, Simon Fraser University, Vancouver Canada Summer 2014

More information

Advanced IPD meta-analysis methods for observational studies

Advanced IPD meta-analysis methods for observational studies Advanced IPD meta-analysis methods for observational studies Simon Thompson University of Cambridge, UK Part 4 IBC Victoria, July 2016 1 Outline of talk Usual measures of association (e.g. hazard ratios)

More information

Clinical Trials A Practical Guide to Design, Analysis, and Reporting

Clinical Trials A Practical Guide to Design, Analysis, and Reporting Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting

More information

Score Tests of Normality in Bivariate Probit Models

Score Tests of Normality in Bivariate Probit Models Score Tests of Normality in Bivariate Probit Models Anthony Murphy Nuffield College, Oxford OX1 1NF, UK Abstract: A relatively simple and convenient score test of normality in the bivariate probit model

More information

RESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry

RESEARCH ARTICLE. Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry DOI:http://dx.doi.org/.734/APJCP.22.3..568 RESEARCH ARTICLE Comparison between Overall, Cause-specific, and Relative Survival Rates Based on Data from a Population-based Cancer Registry Mai Utada *, Yuko

More information

Cross-validated AUC in Stata: CVAUROC

Cross-validated AUC in Stata: CVAUROC Cross-validated AUC in Stata: CVAUROC Miguel Angel Luque Fernandez Biomedical Research Institute of Granada Noncommunicable Disease and Cancer Epidemiology https://maluque.netlify.com 2018 Spanish Stata

More information

Up-to-date survival curves of children with cancer by period analysis

Up-to-date survival curves of children with cancer by period analysis British Journal of Cancer (3) 88, 1693 1697 & 3 Cancer Research UK All rights reserved 7 9/3 $25. www.bjcancer.com Up-to-date survival curves of children with cancer by period analysis *,1 1 Department

More information

Notes for laboratory session 2

Notes for laboratory session 2 Notes for laboratory session 2 Preliminaries Consider the ordinary least-squares (OLS) regression of alcohol (alcohol) and plasma retinol (retplasm). We do this with STATA as follows:. reg retplasm alcohol

More information

Bayesians methods in system identification: equivalences, differences, and misunderstandings

Bayesians methods in system identification: equivalences, differences, and misunderstandings Bayesians methods in system identification: equivalences, differences, and misunderstandings Johan Schoukens and Carl Edward Rasmussen ERNSI 217 Workshop on System Identification Lyon, September 24-27,

More information

Report on Cancer Statistics in Alberta. Breast Cancer

Report on Cancer Statistics in Alberta. Breast Cancer Report on Cancer Statistics in Alberta Breast Cancer November 2009 Surveillance - Cancer Bureau Health Promotion, Disease and Injury Prevention Report on Cancer Statistics in Alberta - 2 Purpose of the

More information

Cancer projections National Cancer Registry

Cancer projections National Cancer Registry Cancer projections 25-235 National Cancer Registry Published by the National Cancer Registry 28 Building 68, Cork Airport Business Park, Kinsale Road, Cork, Ireland Telephone 21-431814 Email Web site info@ncri.ie

More information

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.

Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. Paper SP02 Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. José Luis Jiménez-Moro (PharmaMar, Madrid, Spain) Javier Gómez (PharmaMar, Madrid, Spain) ABSTRACT

More information

Statistical Science Issues in HIV Vaccine Trials: Part I

Statistical Science Issues in HIV Vaccine Trials: Part I Statistical Science Issues in HIV Vaccine Trials: Part I 1 2 Outline 1. Study population 2. Criteria for selecting a vaccine for efficacy testing 3. Measuring effects of vaccination - biological markers

More information

Estimating Testicular Cancer specific Mortality by Using the Surveillance Epidemiology and End Results Registry

Estimating Testicular Cancer specific Mortality by Using the Surveillance Epidemiology and End Results Registry Appendix E1 Estimating Testicular Cancer specific Mortality by Using the Surveillance Epidemiology and End Results Registry To estimate cancer-specific mortality for 33-year-old men with stage I testicular

More information

A Brief Introduction to Bayesian Statistics

A Brief Introduction to Bayesian Statistics A Brief Introduction to Statistics David Kaplan Department of Educational Psychology Methods for Social Policy Research and, Washington, DC 2017 1 / 37 The Reverend Thomas Bayes, 1701 1761 2 / 37 Pierre-Simon

More information

Should relative survival be used with lung cancer data?

Should relative survival be used with lung cancer data? British Journal of Cancer (22) 6, 84 89 & 22 Cancer Research UK All rights reserved 7 92/2 www.bjcancer.com Should relative survival be used with lung cancer data? SR Hinchliffe*,, MJ Rutherford, MJ Crowther,

More information

Survival analysis beyond the Cox-model

Survival analysis beyond the Cox-model Survival analysis beyond the Cox-model Hans C. van Houwelingen Department of Medical Statistics Leiden University Medical Center The Netherlands jcvanhouwelingen@lumc.nl http://www.medstat.medfac.leidenuniv.nl/ms/hh/

More information

Poisson regression. Dae-Jin Lee Basque Center for Applied Mathematics.

Poisson regression. Dae-Jin Lee Basque Center for Applied Mathematics. Dae-Jin Lee dlee@bcamath.org Basque Center for Applied Mathematics http://idaejin.github.io/bcam-courses/ D.-J. Lee (BCAM) Intro to GLM s with R GitHub: idaejin 1/40 Modeling count data Introduction Response

More information

Multivariable Cox regression. Day 3: multivariable Cox regression. Presentation of results. The statistical methods section

Multivariable Cox regression. Day 3: multivariable Cox regression. Presentation of results. The statistical methods section Outline: Multivariable Cox regression PhD course Survival analysis Day 3: multivariable Cox regression Thomas Alexander Gerds Presentation of results The statistical methods section Modelling The linear

More information

Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.

Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of

More information

Vincent Y. F. He 1*, John R. Condon 1, Peter D. Baade 1,2, Xiaohua Zhang 3 and Yuejen Zhao 3

Vincent Y. F. He 1*, John R. Condon 1, Peter D. Baade 1,2, Xiaohua Zhang 3 and Yuejen Zhao 3 He et al. Population Health Metrics (2017) 15:1 DOI 10.1186/s12963-016-0118-9 RESEARCH Open Access Different survival analysis methods for measuring long-term outcomes of Indigenous and non-indigenous

More information

Estimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little

Estimands, Missing Data and Sensitivity Analysis: some overview remarks. Roderick Little Estimands, Missing Data and Sensitivity Analysis: some overview remarks Roderick Little NRC Panel s Charge To prepare a report with recommendations that would be useful for USFDA's development of guidance

More information